After signing up, you'll start to receive regular news updates from us.
Which Diseases will RNAi Drugs be Used to Treat and what Barriers will RNAi Drugs Need to Overcome
Complete the form below to unlock access to ALL audio articles.
Research and Markets has announced the addition of "Gene Silencing with RNA Interference: A New Generation of Pharmaceuticals" to their offering.
For 50 years since the discovery the DNA double helix, RNA has been regarded as a necessary but not too exciting participant in protein synthesis.
However, when it was reported that a specific type of DNA could silence plant genes, everything changed.
As it turns out, RNAi is the natural process the body uses to protect itself against infections and to control development. Hopes that the RNAi process can be used to treat human disease are very high.
The market for RNAi interference is projected to explode both as a research tool and as a new class of pharmaceuticals, but is the technology ready to support the expected growth?
The purpose of this report is to map and assess the technology development status of RNAi and to determine which parts of the technology are ready for primetime.
This report contains a forecast of how the technology will evolve, including nearly unpopulated "white-space".
It also contains master tables of company focuses (strengths and weaknesses), a starting point to find partners or acquisitions.
RNAi technology is broken into 7 main competitive categories and 82 specific technology focuses.
Also included in this report is a table of the 50 most actively patenting organizations in RNAi - the leaders and their focuses.
Alongside a master table with 2600 companies, organizations and inventors and their focuses.
This report provides technology strategy maps to answer strategic questions such as:
- Is RNAi ready for prime time?
- What diseases will RNAi drugs be used to treat?
- What technology approaches are hot or cold today?
- What barriers will RNAi drugs need to overcome?
- How will the technology evolve?
- What companies will profit form overcoming them?
- What companies will lead the way? Where are they focused?
How can we find the answers? Technology Triage™:
When technology is the driver, marketing research is not enough. Technology analysis must occur in parallel.
Only when technology is analyzed from a marketing perspective can the right investment and product decisions be made.
Unique (patent pending) visualizations the technology development landscape allows us to answer the questions.
Analysis of ~12000 patents and ~13000 scientific references provides a picture of developments from a new perspective.
To complete the assessment, we identified trends in technology developments by categorizing ~12000 RNAi related patents into 82 business relevant categories.
Supplementing the patent trends with information from ~13000 journal references, we were able to assess the significance of the patent trends and to make some educated predictions about the future direction of RNAi technology.
Who can use the information in a TechTriage™ Note?
- Marketing Executives, Directors and Mangers
- Technology Program Executives, Directors and Managers
- Acquisitions or Licensing Executives, Directors and Managers
- Technology Investors
Companies Mentioned Include: Abbott, Affinium Pharmaceuticals, Alnylam Pharma, Ambion, Inc, Amgen, Ares Trading, Astrazeneca, Baylor, Benitec, Bioneer, Inc, California Institute Of Tech, Cancer Research Technology Limited, Carnegie Institution Of Washington, Cbr Institute For Biomedical Research, Cell Signaling Technology, Cenix, Chiron, Cold Springs Harbor, Columbia U, Cyclacel, Cystic Fibrosis Found, Develogen, Dharmacon, Dna Technologies, Ei_Dupont, Eurogentec, Evotec Neuro, Exelixis, Garching Gmbh (Max Plank), Genecare Research Institute, General Hospital, Gen-Probe, Harvard, Hybridon, Incyte_Genomics, Inex Pharmaceuticals, Integrated Dna, Invitrogen, Isis Pharma, J&J, Johns Hopkins, Lexicon Genetics, Max Planck Society, Medtronic, Merck, Mit, Mwg Biotech Ag, Nastech Pharma Inc, Nektar, Novartis, Oncotherapy Science, Origene_Tech, Pfizer, Quiagen, Ribopharma Ag, Rigel Pharmaceuticals, Rnax, Sigma-Aldrich, Sirna, Stanford University, U. Colorado, U.Mass, U.Penn, U.S. Govt., Ucalif, Wyeth, and Xenogen.
